XKH004 / Kanova Biopharma, Livzon Pharma - LARVOL DELTA

Head-to-head Phase III trial is successful! The first domestically produced IL-17A/F monoclonal antibody is about to be approved for marketing [Google translation] (PhIRDA) - P3 | N=918 | NCT06110676 | Sponsor: Livzon Pharmaceutical Group Inc. | "The primary efficacy endpoint of the study has been achieved . The PASI 100 response rate at week 12 was 49.5% for LZM012 and 40.2% for secukinumab in the control group, showing that LZM012 was non-inferior and superior to secukinumab...The main secondary efficacy endpoint, the PASI 75 response rate at week 4, was 65.7% for LZM012 and 50.3% for the control group with secukinumab, indicating that LZM012 was more effective faster; the PASI 100 response rate at week 52 was 75.9% and 62.6% for the LZM012 320mg Q4W and 320mg Q8W maintenance treatment groups, respectively, indicating that psoriasis patients can benefit sustainably....Based on this, Livzon Group has recently submitted a pre-marketing authorization communication application to the Center for Drug Evaluation (CDE) of the National Medical Products."

China filing • P3 data • Psoriasis

Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review. (PubMed, Am J Clin Dermatol) - "Key agents under investigation include netakimab, vunakizumab, xeligekimab, gumokimab, HB0017, CJM 112, JS005, 608, LZM012, ZL-1102, izokibep, sonelokimab, DC-806, DC-853, and LEO 153339. Both preclinical and clinical trial data for each agent are summarized, with an emphasis on their efficacy, adverse effects, immunogenicity, and future outlooks."

Journal • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Efficacy and Safety of the Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection (XKH004) in Patients with Active Ankylosing Spondylitis: Findings from a 24-Week, Phase 2 Multicenter, Randomized, Placebo-Controlled Study (ACR Convergence 2024) - "Background/Purpose: XKH004, the first recombinant anti-human IL-17A/F humanized monoclonal antibody in China (also known as XKH004), shares the same therapeutic target as Bimekizumab from UCB pharma, the first biologic targeting IL-17 A/F (XKH004 is the second one worldwide). In patients with active AS, various dosages of XKH004 effectively improved disease activity. The safety and tolerability profile were favorable, and no immunogenicity risk was identified for up to 24 weeks."

Clinical • P2 data • Ankylosing Spondylitis • Back Pain • Immunology • Inflammatory Arthritis • Musculoskeletal Pain • Pain • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A

Psoriasis: A Study to Evaluate the Efficacy and Safety of LZM012 (clinicaltrials.gov) - P3 | N=918 | Recruiting | Sponsor: Livzon Pharmaceutical Group Inc.

New P3 trial • Dermatology • Immunology • Psoriasis • Psoriatic Arthritis